Rhode Island Medical Imaging

To make an appointment, call 401-432-2400

For questions about your copay, deductible or cost, call 401-427-7820

Liver Cancers

Liver is a vital human organ which performs many synthetic and metabolic functions.  Primary tumor of the liver, namely hepatocellular carcinoma (HCC), typically arises in the setting of underlying hepatitis and cirrhosis.  Although some HCC can be resected, overwhelming majority of patients with HCC are not surgical or liver transplant candidates and thus require palliative treatment. 

Typical medical cancer management, i.e. intravenous chemotherapy and external beam radiation, are limited in HCC therapy as they have not shown significant survival benefit.  Regional therapies such as transarterial chemoembolization (TACE) and selective internal radiation treatment (SIRT) are minimally invasive therapies which can prolong survival.


Using catheters under fluoroscopic (x-ray) guidance, interventional radiologist can target the delivery of medications and embolic material directly to the tumor. 

Typically the common femoral artery is accessed with a needle and subsequently a catheter is advanced into the arteries which supply the tumor and chemotherapeutic medications and embolic materials are directly delivered.  Thus, the systemic side effects of the medications are reduced and the cancer is treated with greater amount of anti-cancer medication. 

Two to four sessions are typically required to obtain optimal results.  Although not curative, studies have shown survival benefits.  In some cases, tumors can be shrunken and allow surgical resection for cure.  Patients are admitted overnight for observation and typically discharged the next day.   Patients are followed clinically as well as with imaging tests, e.g. CT scans.


Selective internal radiation therapy is a more novel technique in which the liver tumors (primary or metastatic) are treated with radiation from the inside the body rather than from traditional external source.  Microscopic particles bound to yttrium90 are delivered directly and exclusively to the artery supplying the cancer.  Yttrium90 then kills the tumor as it decays.  SIRT is performed by an interventional radiologist with catheters under fluoroscopic guidance.  SIRT is an outpatient procedure performed in the hospital setting.

For more information or questions please call Interventional Radiology at Rhode Island Medical Imaging at (401)-421-1924.

Picture shows the catheter passage way to the artery supply the liver tumors seen in green.

CT scan of a large enhancing left hepatocellular carcinoma

Transarterial Chemoembolization:  Radiograph demonstrates delivery of chemotherapy medication emulsified in lipiodol directly into the left hepatic artery supplying the tumor.


About RIMI
Latest News & Updates
East Providence I-195 West On-ramp Closures
Posted: 04.02.18

As RIDOT replaces the Parkway Ramp Bridge in East Providence (see below for more information), they will need to close the I-195 West on-ramps from Veterans Memorial Parkway and Warren Avenue in East Providence beginning Wednesday, April 4. Get detour information here.

Traffic heading north on the Parkway will follow a detour using Lyon Avenue to Warren Avenue to Broadway. Local traffic on the Parkway north of Lyon Avenue can use Mauran Avenue (the last street before the Parkway on-ramp) to Burgess Avenue to reach Warren Avenue and the detour route to Broadway.

Those heading to destinations on the East Side of Providence may wish to follow Valley Street to North Brow Street to Massasoit Avenue to use the Henderson Bridge as an alternate detour. Motorists also may wish to use Pawtucket Avenue or the Wampanoag Trail to the East Shore Expressway for I-195 West access.

The bridge replacement will be completed in late fall, however work on the nearby Washington Bridge will extend its reopening until the end of 2019.

Lung cancer expo highlights latest research, reinforces need for funding
Posted: 11.28.17

Despite lung cancer causing the most fatalities of any cancer in the United States, funding for lung cancer research has not drastically improved for many years. The American Lung Association drove home this message and other insights during the Lung Force Expo at the Crowne Plaza Hotel on November 8, 2017.